ISSN 1214-0287 (on-line), ISSN 1214-021X (printed)
J Appl Biomed
Volume 9 (2011), No 2, p. 111-118
DOI 10.2478/v10136-009-0036-2

Ectopic osteogenesis with immortalized human bone marrow stromal stem cells and heterologous bone

Yong Teng, Yunyu Hu, Xusheng Li, Yucheng Guan, Junhao Gui

Address: Yong Teng, Department of Orthopedics, Orthopedic Center of PLA, Urumqi General Hospital, Lanzhou Military Region, Xinjiang Uygur Autonomous Region 830000, China
tangyunn@yeah.net

Received 18th October 2010.
Published online 2nd November 2010.

Full text article (pdf)
Full text article (html)
Abstract in xml format

SUMMARY
To resolve the problem of the insufficient availability of seed cells and to provide seed cells for tissue engineering research, an immortalized human bone marrow stromal stem cell line (MSCxj cells) was established in our department to investigate the ectopic osteogenesis of MSCxj cells.
MSCxjs were grown with a heterogeneous bone scaffold for 48 h. Three groups were included: A: MSCxjs of 35 PDs were maintained with heterogeneous bone; B: MSCxjs of 128 PDs were maintained with heterogeneous bone; and C: heterogeneous bone alone. Tetracycline fluorescence staining, H&E staining, and ponceau staining, immunohistochemistry and bone histomorphometry were performed. At the same time, scanning electron microscopy was conducted to detect the growth of MSCxjs and heterogeneous bone.
Scanning electron microscopy showed favorable adherence of MSCxjs to heterogeneous bone. A large number of newly generated filamentous extracellular matrix and fine granular materials were found to cover the cells. The results from staining showed that the osteogenesis was not obvious in group A/B 4 weeks after transplantation. Eight weeks after implantation, osteoid matrix deposition was noted in and around the heterogeneous bone in group A/B. Twelve weeks after implantation, osteogenesis was increased in group A/B. There were no significant differences in the time course for bone formation and the amount of newly generated bone between group A/B.
Like primary hBMSCs, MSCxj cells have favourable ectopic osteogenesis and can be applied as seeded cells in bone tissue engineering.

KEY WORDS
tissue engineering; immortalization; human; bone marrow stromal cells; ectopic osteogenesis; xenografts

REFERENCES
Bauer Tw, Muschler GF. Bone graft materials; an overview of the basic science. Clin Orthop. 371: 10-14, 2000.
[PubMed]

Bedi A, Feeley BT, Williams RJ. 3rd Management of articular cartilage defects of the knee. J Bone Joint Surg Am. 92: 994-1009, 2010.
[CrossRef] [PubMed]

Byun IS, Sarkar SK, Anirban Jyoti M, Min YK, Seo HS, Lee BT, Song HY. Initial biocompatibility and enhanced osteoblast response of Si doping in a porous BCP bone graft substitute. J Mater Sci Mater Med. 21: 1937-1947, 2010.
[CrossRef] [PubMed]

Cordonnier T, Layrolle P, Gaillard J, Langonne A, Sensebe L, Rosset P, Sohier J. 3D environment on human mesenchymal stem cells differentiation for bone tissue engineering. J Mater Sci Mater Med. 21: 981-987, 2010.
[CrossRef] [PubMed]

He H, Cao J, Wang D, Gu B, Guo H, Liu H. Gene-modified stem cells combined with rapid prototyping techniques: a novel strategy for periodontal regeneration. Stem Cell Rev. 6: 137-141, 2010.
[CrossRef] [PubMed]

Hesse E, Kluge G, Atfi A, Correa D, Haasper C, Berding G, Shin HO, Viering J, Langer F, Vogt PM, Krettek C, Jagodzinski M. Repair of a segmental long bone defect in human by implantation of a novel multiple disc graft. Bone. 46: 1457-1463, 2010.
[CrossRef] [PubMed]

Hodgkinson T, Yuan XF, Bayat A. Adult stem cells in tissue engineering. Expert Rev Med Devices. 6: 621-640, 2009.
[CrossRef] [PubMed]

Hu YY, Lu YP. Experimental studies on the repair of bone defect through bone xenograft (in Chinese). Chin J Orthop. 10: 33-36, 1990.

Itescu S, Schuster MD, Kocher AA. New directions in strategies using cell therapy for heart disease. J Mol Med. 81: 288-296, 2003.
[PubMed]

Jukes JM, van Blitterswijk CA, de Boer J. Skeletal tissue engineering using embryonic stem cells. J Tissue Eng Regen Med. 4: 165-180, 2010.
[CrossRef] [PubMed]

Li WJ, Tuli R, Okafor C, Derfoul A, Danielson KG, Hall DJ, Tuan RS. A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells. Biomaterials. 26: 599-609, 2005.
[CrossRef] [PubMed]

Liu Y, Ramanath HS, Wang DA. Tendon tissue engineering using scaffold enhancing strategies. Trends Biotechnol. 26: 201-209, 2008.
[CrossRef] [PubMed]

Lv R, Yang G. Comparisons between plastic undecalcified sections, paraffin-embedded sections and gelatin immersed sections (in Chinese). Chin J Clin Exp Pathol. 15: 464-465, 1999.

Lv R, Xu XZ, Wang J. Sectioning and staining of plastic-embedded and undecalcified sections (in Chinese). Chin J Clin Exp Pathol. 18 :342, 2002.

Lv R, Wang J, Xu XZ. Bone histology and image analysis of plastic-embedded and undecalcified sections (in Chinese). Chin J Clin Exp Pathol. 22: 369-370, 2006.

Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EGA, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 108: 2114-2120, 2006.
[CrossRef] [PubMed]

Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation. 83: 783-790, 2007.
[CrossRef] [PubMed]

Ren HY, Zhao QJ, Xing W. Differentiation of human umbilical cord derived mesenchymal stem cells into low immunogenic and functional hepatocyte-like cells in vitro (in Chinese). Zhongguo Yi Xue Ke Xue Yuan Xue Bao 32:190-194, 2010.
[PubMed]

Revell CM, Athanasiou KA: Success rates and immunologic responses of autogenic, allogenic, and xenogenic treatments to repair articular cartilage defects. Tissue Eng Part B Rev. 15: 1-15, 2009.
[CrossRef] [PubMed]

Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A. Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol. 222: 23-32, 2010.
[CrossRef] [PubMed]

Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther. 9: 747-756, 2004.
[CrossRef] [PubMed]

Sundelacruz S, Kaplan DL. Stem cell- and scaffold-based tissue engineering approaches to osteochondral regenerative medicine. Semin Cell Dev Biol. 20: 646-655, 2009.
[CrossRef]

Teng Y, Hu YY, Wang HG. Study of hTERT activating telomerase in human bone marrow mesenchyme stem cells (in Chinese). Orthop J China. 7: 1253-1256, 2007a.

Teng Y, Hu YY, Wang Z. Differentiation of human bone marrow-derived mesenchymal stem cells into chondrocytes in vitro (in Chinese). Chin J Exp Surg. 12: 17-19, 2007b.

Yuan Z, Zhao L, Hu YY. Combined use of rhBMP 2/BCB and periosteum in repairing segmental defects in radii of rabbits. Chin J Orthop. 19: 45-49+65, 1999.

Yuan Z, Hu YY, Li MQ. Therapeutic effect of anti-infective reconstituted bone xenograft on osteomyelitis in proximal tibia of rabbits (in Chinese). Chin J Orthop. 23: 230-234, 2003a.

Yuan Z, Zhao L, Hu YY. Anti-infective reconstituted bone xenograft used for primary bone grafting to repair contaminated defect in the radius in dogs (in Chinese). Chin J Traumatol. 6: 86-90, 2003b.
[PubMed]

Zhao CG, Hu YY, Lv R. The osteoinductivity and the dose-effect relationship with implantation of reconstituted bone xenograft: experimental study (in Chinese). Chin J Surg. 36: 627-629, 1998.
[PubMed]

Zou XH, Cai HX, Yin Z, Chen X, Jiang YZ, Hu H, Ouyang HW. A novel strategy incorporated the power of mesenchymal stem cells to allografts for segmental bone tissue engineering. Cell Transplant. 18: 433-441, 2009.
[CrossRef] [CrossRef] [PubMed] [PubMed]
CITED

0


BACK